Fosun Pharma: Participation in the establishment of special fund registration completed. Uncertainty remains in asset sales.

Fosun Pharma announced that in September 2025 and March 2026, its controlling subsidiary Fosun Pharma Industry plans to participate in the establishment of a special fund to sell 100% equity and debt of Shanghai Klonbio. Recently, the special fund has been filed with the China Securities Investment Fund Association. As of April 23, 2026, the conditions for the signing of the transfer agreement have not been fully met, and there is uncertainty in the transfer. If the agreement is not signed on time or is terminated in advance, the transfer will be terminated and the special fund will be dissolved and liquidated.